Analytical Data
-
Gene name
CDK9-CCNT1
- Application
-
Alternative Names
C-2k; CDC2L4; PITALRE; TAK; CDC2-Related Kinase; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Tat-associated kinase complex catalytic subunit
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P50750
-
Expression Region
Asp104~Phe315
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK9-CCNT1 recombinant protein is a focus of research due to its critical role in the regulation of transcription and cell cycle progression. Cyclin-dependent kinase 9 (CDK9) is a key player in the phosphorylation of the C-terminal domain (CTD) of RNA polymerase II, which is essential for the transcriptional elongation phase. Its activity is tightly regulated and often associated with various cyclins, including cyclin T1 (CCNT1), which forms a complex that enhances CDK9 activity. The CDK9-CCNT1 complex is particularly significant in the context of certain oncogenic pathways, particularly in cancers where deregulation of transcriptional control leads to uncontrolled cell proliferation. Moreover, this protein complex has emerged as a potential therapeutic target; inhibitors of CDK9 have shown promise in preclinical studies for treating various malignancies, including leukemia and solid tumors. By studying the structure and function of CDK9-CCNT1 recombinant protein, researchers aim to elucidate its precise mechanisms of action and identify effective inhibitors. Understanding the interactions and regulatory mechanisms of this complex can provide insights into novel strategies for cancer therapy, making the study of CDK9-CCNT1 recombinant protein an important area in molecular biology and pharmacology.
